News and Press Releases
CFTR Modulators Positive Early Study Results for Next-Generation CFTR Modulators

New data show positive results in individuals with a single F508del mutation as well as people with two copies of F508del and support continued development of triple combination therapies. 

| 6 min read
Research | CFTR Modulators | Drug Pipeline FDA Approves Ivacaftor for 23 Additional CFTR Mutations

The U.S. Food and Drug Administration (FDA) today approved ivacaftor (Kalydeco®) for people ages 2 and older who have at least one of 23 residual function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

| 3 min read